Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Report Examines Zimbabwean Refugees In South Africa
According to a report released Tuesday by Medicins Sans Frontiers (MSF), "Zimbabweans continue to cross the border [into South Africa] every day, legally and illegally, in massive numbers as a matter of survival," AFP/Google.com reports (AFP/Google.com, 6/2). An estimated "three million Zimbabweans - about a quarter of the entire population" have fled "the economic collapse and human rights abuses at home, as well as a cholera outbreak that has infected about 100,000 people," according to the BBC, and the "inauguration in February of a fractious power-sharing government in Zimbabwe has not stemmed the flight" (BBC, 6/2).

Requirements For Using E-Health Begin To Emerge; Public Input Needed, Experts Say
The American Recovery and Reinvestment Act (a.k.a. The Stimulus) set aside billions of dollars for hospitals to acquire electronic medical record systems, but one requirement for hospitals hoping to receive the money will be to share patient records with other facilities, the Dallas Morning News reports. "North Texas hospitals have talked for years about ways to share these records but have been unable to agree. Some participants in the discussions have said that"s because of concerns they might lose patients to competing hospitals" (Landers, 6/24).
News of the day
A Novel Approach For Treating Cognitive Impairments Identified By Animal Model For Schizophrenia
Researchers have been seeking a safe and effective way to treat cognitive impairments associated with schizophrenia by enhancing N-methyl-D-aspartate (NMDA) glutamate receptors. Functional deficits in NMDA receptors may contribute to the underlying neurobiology of this disorder. The first generation of studies trying to stimulate NMDA receptors administered large amounts of substances, like glycine or D-serine, which indirectly enhance NMDA receptor function. While there were some positive reports of efficacy, findings across studies were more inconsistent than was hoped.
Mental Health

Living Cell Technologies' Diabetes Clinical Trial Authorized By New Zealand Government

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) announced that the New Zealand Minister of Health, the Honourable Tony Ryall, has authorized LCT"s New Zealand Phase I/IIa clinical trial of DIABECELL(R) for insulin dependent diabetes. The authorization confirms the conditions announced on 19 June 2009. One condition of the new authorization limits participation in the trial to patients with poorly controlled (brittle) diabetes. The remaining conditions are procedural rather than substantive in nature and LCT and the Middlemore Hospital clinical team conducting the trial, have requested the Regional Ethics Committee formally accept the changes required by the Minister. LCT CEO Dr Paul Tan said: "We are pleased that the conditions have been finalized and LCT looks forward to commencing the trial within the next two months with the acceptance of the changes by the Ethics Committee." Professor Bob Elliott, LCT Founder and Medical Director added: "The New Zealand diabetes trial is another major milestone for LCT. With two diabetes patients not requiring insulin following implants with encapsulated pig islet cells in our first study in Russia, we expect to see further benefit in more patients as we use higher doses of DIABECELL(R) in the New Zealand trial." LCTs Phase I/IIa clinical trial in Russia started with a low dose of DIABECELL(R). In May 2009 LCT reported preliminary data showing sustained long term clinical benefit in patients treated with the DIABECELL(R) implant with no remarkable adverse events. Remarkably, two of seven patients given implants are now off insulin injections. The New Zealand trial allows LCT to extend its Phase I/IIa clinical data with eight patients, four of whom are to receive double the initial dose used in Russia followed by four patients to receive triple the dose. Dr John Baker, Clinical Director and Diabetes Physician at Middlemore Hospital, Auckland, who will be conducting the trial said, "There are many patients with poorly controlled diabetes who would qualify for this trial." DIABECELL(R) is designed to normalize blood glucose levels in type 1 diabetes sufferers. DIABECELL(R) comprises encapsulated porcine insulin-producing cells which can be administered without the need to use immunosuppressive drugs. Type 1 diabetes occurs when the body"s own immune system destroys the insulin-producing cells of the pancreas (called beta cells). Five to 10 percent of the more than 200 million diabetics worldwide have insulin dependent type 1 diabetes. Type 1 diabetes is associated with kidney failure, blindness, nerve damage, life-threatening cardiovascular disease and limb amputations. Current treatment options include multiple daily injections of insulin. Living Cell Technologies


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009